We’re putting the finishing touches on something special — ordering opens soon. Stay tuned.
← Back to Catalog

Tirzepatide

Tirzepatide vial frontTirzepatide vial back
Loading...

Summary

LY3298176

Tirzepatide is a once-weekly injectable that activates two hormone receptors (GLP-1 and GIP) involved in blood sugar control and appetite regulation. Clinical trials showed weight loss of 15-22% and excellent blood sugar control in type 2 diabetes. It's FDA-approved as Mounjaro for diabetes (2022) and Zepbound for weight management (2023).

Current Research
  • GLP-1 and GIP signaling in metabolism
  • Body weight in obesity research
  • Type-2 diabetes and glycemic control
  • Cardiovascular outcomes
Identification
CAS
2023788-19-2
Formula
C225H348N60O68
M.W.
4813.4 g/mol

Key Research Statistics

Dual GIP/GLP-1 Agonist

22.5%Max Weight LossSURMOUNT-1, 72 weeks, 15 mg — highest approved therapy
2.58%HbA1c ReductionHighest ever for any incretin — 54–56% of patients hit HbA1c <5.7%
80%Liver Fat ReductionHepatic steatosis — relative reduction in clinical data
DualGIP + GLP-1 AgonistFirst-in-class twincretin — GIP buffering reduces nausea vs semaglutide
Responder Thresholds — SURMOUNT-1 (15mg)
≥5% Loss91%
≥10% Loss79%
≥15% Loss64%
≥20% Loss50%
SURMOUNT-1 (72 weeks)

Need-to-Know

  • Room Temperature (Lyophilized): 2-3 weeks
  • Refrigerated (Reconstituted): 14–28 days
  • Frozen (Lyophilized): 12+ months
  • Reconstitution Solution: Bacteriostatic water, Sterile water
  • Appearance: White powder

Regulatory Status

FDA-approvedApprovedApproved

FDA-approved for type 2 diabetes and weight management.

Sources: FDA.gov

History

2010s
Patent filed in 2016; trials completed; FDA application in 2021.
2020s
Approved for diabetes (2022); for obesity (2023); for sleep apnea (2024).

3D Structure

27-amino-acid peptide · 4813.4 g/mol

Interactive model
Tirzepatide molecule previewExplore 3D Structure

Tirzepatide at the Cellular Level

Dual GIP/GLP-1 agonist

Mechanism
Tirzepatide cellular mechanism preview

Tirzepatide in the Body

Dual GLP-1/GIP receptor agonist

Metabolic
Tirzepatide in the Body

Research Library

Peer-reviewed studies

From Published Literature

"In adults with obesity or overweight, tirzepatide was associated with body weight reduction and improvements in insulin sensitivity and β‑cell function."

SURMOUNT‑1 investigatorsPeer-reviewed clinical study
Verify on PubMed